Reconsidering the switch from low-molecular-weight heparin to unfractionated heparin during pregnancy

Am J Perinatol. 2014 Sep;31(8):655-8. doi: 10.1055/s-0033-1359719. Epub 2013 Dec 11.

Abstract

Venous thromboembolic disease accounts for 9% of all maternal deaths in the United States. In patients at risk for thrombosis, common practice is to start prophylactic doses of low-molecular-weight heparin and transition to unfractionated heparin during the third trimester, with the perception that administration of neuraxial anesthesia will be safer while on unfractionated heparin, as spinal/epidural hematomas have been associated with recent use of low-molecular-weight heparin. In patients receiving prophylactic doses of unfractionated heparin, neuraxial anesthesia may be placed, provided the dose used is 5,000 units twice a day. The American Society of Regional Anesthesia and Pain Medicine guidelines recognize that the safety of neuraxial anesthesia in patients receiving more than 10,000 units per day or more than 2 doses per day is unknown, limiting the theoretical benefit of unfractionated heparin at doses higher than 5,000 units twice a day.

Publication types

  • Review

MeSH terms

  • Anesthesia, Obstetrical / adverse effects
  • Anticoagulants / therapeutic use*
  • Drug Substitution
  • Female
  • Hematoma, Epidural, Spinal / etiology
  • Hematoma, Epidural, Spinal / prevention & control
  • Heparin / therapeutic use*
  • Heparin, Low-Molecular-Weight / therapeutic use*
  • Humans
  • Pregnancy
  • Pregnancy Complications, Hematologic / prevention & control*
  • Pregnancy Trimester, Third
  • Venous Thromboembolism / prevention & control*

Substances

  • Anticoagulants
  • Heparin, Low-Molecular-Weight
  • Heparin